AsepticSure™ Developments

AsepticSureGlobe1

AsepticSure™

It is anticipated that AsepticSure™ will be extremely cost effective and adaptable to virtually any situation anywhere and have a global reach.

Mock Trials

The mock trials are now producing the same results in terms of sterilization that were first achieved in the small laboratory unit.

March 15, 2010 –  The AsepticSure™ system is capable of decontamination to the previously unobtainable 6 log standard on all hospital surfaces, hard or soft.

The AsepticSure™ hospital sterilization system has completed the first and second full round of room scale trials eliminating all pathogens across the ‘Super Bug’ spectrum on stainless steel surfaces, porcelain, formica and many common fabrics at a reliable 6 log (99.9999%) kill or greater.

Of commercial significance in a hospital setting is the fact that the AsepticSure™ system is now able to greatly reduce the time required to achieve 6 log kills on hard surfaces to 30 minutes of exposure.  With the charge time and destruct time for reuse of the space factored in, that translates to a room turn around time of 80 minutes, a 40 minute saving in total turn around time from the original target of 2 hours.

Fabric exposure requires an additional 15 minutes to achieve the same 6 log kill rate, which represents a full turn around for a thorough cleaning of about 95 minutes for all surface materials.

Given the sum of our results, it now appears that a typical protocol might have a hospital perform a first cleaning of 95 minutes to fully sterilize the space, which would be followed by cleanings, perhaps as infrequently as one time per week for lower risk settings, requiring only 80 minutes to complete.

Not only is AsepticSure™ continuing to demonstrate its superlative antimicrobial efficacy, it is increasingly becoming apparent that it will be viewed as a practical necessity easily managed by trained hospital maintenance staff without putting rooms out of service for unacceptable periods of time.

March 8, 2010 – The successful completion of the first full round of room scale testing with AsepticSure™ sterilization system indicated all pathogens of cause with HAIs were completely eliminated at concentrations well above 6 log. These results have confirmed the laboratory findings reported earlier this year, but what is of even greater significance are the insights gained into the technical modifications necessary to accommodate the unique requirements of decontaminating within a hospital environment.

Work will continue on the room scale testing program in order to expand understanding of factors that will enhance the efficiency and effectiveness of AsepticSure™, particularly when dealing with contaminated textiles in time sensitive hospital spaces.

To meet the unique challenges of hospital acquired infections, Medizone has assembled an international team of professional engineers who are finalizing design of our first pre-manufacturing prototype to be used in hospital beta testing, which will commence later this spring.

Medizone will build four highly instrumented prototype units for use in its hospital program, thereby enabling precise performance assessment of all AsepticSure™ systems as concurrent outcome measures, which will form the basis for final production design work, manufacturing and ultimately commercialization later this year.

February 4, 2010: AsepticSure™ Hospital Sterilization System demonstrates total eradication of Super Bugs. Every full scale test run completed in the hospital room mock up facility has resulted in the total elimination of all bacteria present in the room.

In this phase of development, Medizone’s scientific team will attempt to confirm, in a more realistic hospital setting, recent laboratory findings indicating extremely high antibacterial efficacy for its novel technology (6-7.2 log reductions) against the primary causative agents of hospital acquired infections (HAIs), sometimes referred to as “Super Bugs”.

MZEI has now completed multiple runs with very high concentrations of MRSA, VRE and E coli samples that were distributed throughout the test room. In every instance, the AsepticSure™ system produced greater than 6 log (99.9999%) reductions, which by definition, is sterilization. It is noteworthy in this regard that there was absolutely no growth on any of the artificially contaminated surfaces exposed to the AsepticSure™ process.

The intention now is to systematically collect empirically verifiable scientific data on all the remaining causative agents of HAIs. Given these recent results in a full room test setting which precisely mirrors the laboratory set up, the same results are expected with all remaining bacteria as well as Bacillus subtilis, the recognized surrogate for Anthrax.
While more testing and data acquisition must be completed before moving into hospital beta testing, it now seems certain that AsepticSure™ will deliver as promised.

A concern has been the protection of the expensive electronics found throughout hospitals. The electronic testing program will now be intensified to assure false assumptions and not made.

March 8, 2010, Medizone International, Inc. announced today that it has successfully completed the first full round of room scale testing with its AsepticSure™ sterilization system. “Across the board”, commented Dr Michael Shannon, “all pathogens of cause with HAIs were completely eliminated from stainless steel surfaces at concentrations well above 6 log. These results have confirmed the laboratory findings reported earlier this year, but what is of even greater significance are the insights gained into the technical modifications necessary to accommodate the unique requirements of decontaminating within a hospital environment.”

Work will continue on the room scale testing program in order to expand our understanding of factors that will enhance the efficiency and effectiveness of AsepticSure™, particularly when dealing with contaminated textiles in time sensitive hospital spaces.

Third Round Trials

January 5. 2010: Third Round of Laboratory Testing Complete
Third Round Testsing: Medizone International, Inc. third round of testing and data logging for the enhanced AsepticSure™ technology is now complete. Test results achieved over the past two months now predictably demonstrate greater than 6 logs of bacterial “kill” across the full spectrum of hospital contaminants including MRSA, C difficile, E coli, Pseudomonas aeruginosa and VRE in addition to the internationally accepted surrogate for Anthrax, Bacillus subtilis.

Significantly, these results have been replicated on more than a single surface material. “This latest round of laboratory testing has confirmed beyond any reasonable doubt that our enhanced AsepticSure™ technology can reliably achieve sterilization standards for virtually any bacterial contaminant found in a hospital setting,” stated Dr. Michael Shannon, Medizone’s Director of Medical Affairs.

Medizone’s full scale prototype unit has been completed and demonstrated in “dry” runs (bacteria free) that it can reach both the charge time and saturation requirements of its design criteria. The ability to replicate the exact atmosphere of the laboratory test unit in a full sized room is considered a crucial step in achieving the same 6 log bactericidal action in hospital settings.

December 1. 2009: Testing Breaks “6 Log” Decontamination Barriers
Medizone International, Inc. announced that in tests involving proprietary AsepticSure™ technology, it continues to break “6 log” decontamination barriers, this time with two very different spore forming bacteria, Clostridium difficile and Bacillus subtilis. These results clearly establish AsepticSure™ as an extremely potent sporicidal technology.

“The implications of a 6.7 log reduction (99.99997 %) in C. difficile are indeed significant for the entire health care system,” stated Dr Michael Shannon, Director of Medical Affairs for Medizone. “However, even though our findings for Bacillus subtilis are preliminary, the potential of being able to eliminate 99.999992% (7.2 log kill) of an internationally accepted surrogate for Anthrax in 90 minutes will have national security implications.”

Medizone believes that a field hardened variant of the AsepticSure™ hospital unit currently being readied for scale up testing will have wide bio defense applications internationally as it will be easily deployable in response to virtually any terrorist assault, extremely effective against a broad range of lethal pathogens, easy to manage and maintain and most importantly, it has the potential to save lives.

Medizone Reliably and Predictably Able to Break Through 6 Log Barrier with MRSA
Medizone International, Inc. (MZEI.OB) announces an ability to achieve a level of bacterial decontamination heretofore unseen in open space settings using conventional means.

Dr Michael E. Shannon, Director of Medical Affairs, Medizone International stated, “our research team has pressed hard over the last few months to systematically evaluate various decontamination options involving numerous technological approaches in combination, and to our surprise, we have managed reliably and predictably to break through the 6 log barrier with MRSA. This unexpected development will significantly expand the utility for AsepticSure™, since by definition, any bacterial reduction beyond 6 logs (99.9999%) is considered STERILIZATION.

This unique combination of technologies and protocols will now be tested on C difficile, E coli, Pseudomonas aeruginous, and VRE with the expectation that AsepticSure™ will achieve the same degree of incremental improvement over the 4 to 5 log reductions we have already demonstrated with those pathogens in earlier trials.”

Medizone International is preparing a second patent filing to cover these developments while construction and instrumentation of an expanded laboratory setting at the company’s Innovation Park, Queens University laboratory continues in preparation for full room scale-up testing of its equipment to commence in December.

Second Round Trials

Results from the second series of trials demonstrated a 5 log reduction (99.999%) in Pseudomonas Aeruginousa and a 4.4 log reduction (99.994%) in Methicillin Resistant Staph Aureus (MRSA).

AsepticSure™ Hospital Sterilization System
In parallel research conducted at BioZone Corporation, Medizone’s engineering development partner, it was confirmed the AsepticSure™ hospital sterilization system can charge a room of 1,065 cubic feet to the target ozone level in less than 15 minutes, which is followed by the ozone decontamination phase. The same room can then be returned to a habitable standard (less than 0.02 ppm ozone) in 13 minutes using a separate ozone destruct technology. This confirms the start to finish time to complete the entire decontamination process can be achieved with minimal disturbance to normal hospital flow patterns.

Commercial Viability of AsepticSure™ Hospital Sterilization System
From a commercial viewpoint, the higher the “kill rate” in the shortest turn around time, the more favorably physicians and hospital administrators will view the system. Accordingly, Medizone now believes that the performance profile of its AsepticSure™ Sterilization System will exceed all the prerequisite requirements of affordability, practicability and unmatched efficacy, which will catapult it into the world market.

Commercial Viability of AsepticSure™ Hospital Sterilization System

From a commercial viewpoint, the higher the “kill rate” in the shortest turn around time, the more favorably physicians and hospital administrators will view the system. Accordingly, Medizone now believes that the performance profile of its AsepticSure™ Sterilization System will exceed all the prerequisite requirements of affordability, practicability and unmatched efficacy, which will catapult it into the world market.

Medizone International, Inc., is a research and development company engaged in developing its AsepticSure™ technology to decontaminate and sterilize hospital surgical suites, emergency rooms, intensive care units, schools and other critical infrastructure. Mock-up trials are scheduled to begin in January for both public (hospital) and government (bio-terrorism countermeasures) applications.

Investor Relations: 415-868-0300
E-mail: operations @ medizoneint.com

Contact:

Medizone International, Inc. (MZEI.OB)

4000 Bridgeway, Suite 401
Sausalito, CA 94965

Telephone: 415-331-0303

Email: operations@medizoneint.com

Investor Relations:

John Pentony

Investor Relations
Medizone International, Inc.

Telephone: (415) 331-0202

E: j.pentony@medizoneint.com

Media Contact:

Gary Hanauer

Media Relations
Medizone International, Inc.

Telephone: (510) 686-1238

E: GarHan@aol.com